BioCentury

8:00 AM GMT, Jan 31, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 1/28 cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Brean Murray Jonathan Aschoff Price target Buy -2% $82.34
Aschoff raised his target to $93 from $83 after updating his model and taking into account projected revenues out to 2014 for Soliris eculizumab and adding revenue for anti-kidney transplant rejection. The humanized mAb, which targets complement 5 (C5), is approved in Canada, EU, U.S. and Japan to

Read the full 880 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.